elranatamab
pfizer
['mmsm', 'multiple myeloma', 'elranatamab']
patients with penta-or triple-class refractory multiple myeloma who have not received prior b-cell maturation antigen therapy saw an improved objective response rate when elranatamab was given. #mmsm #ash22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.